BRCA2 pathogenic variants

About

Gene context: BRCA2

Biomarker Type: Germline Variant

Present: True

Chromosome: 13

Requires Pathogenic: True


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Niraparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Niraparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Niraparib
EMA (1) FDA (2) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
EMA (1) FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib
EMA (1) FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
EMA (1) FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
EMA (1) FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
EMA (2) FDA (2) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (1) FDA (1) BRCA2 pathogenic variants Pancreatic Adenocarcinoma Olaparib
EMA (1) FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone
FDA (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib
EMA (1) FDA (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
FDA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib
EMA (1) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisolone